Biomolecules (Jun 2021)

Copper Imbalance in Alzheimer’s Disease: Meta-Analysis of Serum, Plasma, and Brain Specimens, and Replication Study Evaluating <i>ATP7B</i> Gene Variants

  • Rosanna Squitti,
  • Mariacarla Ventriglia,
  • Ilaria Simonelli,
  • Cristian Bonvicini,
  • Alfredo Costa,
  • Giulia Perini,
  • Giuliano Binetti,
  • Luisa Benussi,
  • Roberta Ghidoni,
  • Giacomo Koch,
  • Barbara Borroni,
  • Alberto Albanese,
  • Stefano L. Sensi,
  • Mauro Rongioletti

DOI
https://doi.org/10.3390/biom11070960
Journal volume & issue
Vol. 11, no. 7
p. 960

Abstract

Read online

Evidence indicates that patients with Alzheimer’s dementia (AD) show signs of copper (Cu) dyshomeostasis. This study aimed at evaluating the potential of Cu dysregulation as an AD susceptibility factor. We performed a meta-analysis of 56 studies investigating Cu biomarkers in brain specimens (pooled total of 182 AD and 166 healthy controls, HC) and in serum/plasma (pooled total of 2929 AD and 3547 HC). We also completed a replication study of serum Cu biomarkers in 97 AD patients and 70 HC screened for rs732774 and rs1061472 ATP7B, the gene encoding for the Cu transporter ATPase7B. Our meta-analysis showed decreased Cu in AD brain specimens, increased Cu and nonbound ceruloplasmin (Non-Cp) Cu in serum/plasma samples, and unchanged ceruloplasmin. Serum/plasma Cu excess was associated with a three to fourfold increase in the risk of having AD. Our replication study confirmed meta-analysis results and showed that carriers of the ATP7B AG haplotype were significantly more frequent in the AD group. Overall, our study shows that AD patients fail to maintain a Cu metabolic balance and reveals the presence of a percentage of AD patients carrying ATP7B AG haplotype and presenting Non-Cp Cu excess, which suggest that a subset of AD subjects is prone to Cu imbalance. This AD subtype can be the target of precision medicine-based strategies tackling Cu dysregulation.

Keywords